Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Thumbnail

Biodegradable polymer-coated DES safe, effective at 3 years

Three-year results from the BIO-RESORT trial revealed that despite significant differences in stent backbone and polymer coating, the ultrathin sirolimus-eluting stent, very-thin everolimus-eluting stent and thin-strut zotarolimus-eluting stent remained equally safe and effective through follow-up.

Thumbnail

Yearly flu shot decreases risk of death for hypertensive patients

Research presented this month at the ESC Congress in Paris suggests that getting a yearly influenza shot could greatly cut hypertensive patients’ risk of dying during flu season.

Complete revascularization more beneficial than culprit-only PCI after STEMI

Complete revascularization is superior to culprit-lesion-only PCI in patients with both STEMI and multivessel disease, according to results from the COMPLETE trial, published Sept. 1 in the New England Journal of Medicine.

Thumbnail

Study suggests women are overmedicated for heart failure

Research out of the Netherlands suggests current clinical guidelines might recommend overtreatment for women with heart failure, who see maximum benefit from HF drugs at half the dose of men.

Thumbnail

TBI donor hearts found viable for transplant

Using donor hearts from patients who died of traumatic brain injury might be a more viable option for transplant candidates than previously thought, according to an analysis published in the Journal of the American Heart Association Aug. 30.

FDA clears 1st cuffless BP monitors

Biomedical tech company Biobeat has received 510K clearance for its noninvasive, cuffless BP-monitoring systems.

Thumbnail

SGLT2 inhibitors cut heart failure risk for T2D patients

SGLT2 inhibitors—namely dapagliflozin—have been linked to a reduced risk of heart failure and death, as well as decreased odds of major adverse cardiovascular events.

Thumbnail

FDA: Cancer risk from ARB recalls ‘likely much lower’ than estimates

Months after the latest losartan recall and more than a year after drug companies first started pulling bulk lots of angiotensin II receptor blockers (ARB) from pharmacy shelves, the FDA has issued a statement updating the American public on the scope of the situation.